NeuBase Therapeutics, Inc.
DelistedCIK 1173281fmd_02AGCN6P0EJR9JKZW6PGP7MBBPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2006 to Sep 30, 2023, 57 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | – | (0) | (0) | 0 | (0) | 0 | – | – | – | – |
| Research and development | 3 | 4 | 9 | 16 | 17 | 4 | 3 | 7 | 11 | 21 |
| Total operating expenses | 5 | 9 | – | – | – | – | 26 | 17 | 27 | 33 |
| Operating income | (5) | (9) | (18) | (25) | (24) | (14) | (26) | (17) | (27) | (33) |
| Interest expense | 0 | 0 | 0 | – | – | – | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (1) | (0) | 3 | (1) | (0) | 1 | (1) | (0) | 1 | (0) |
| Income before taxes | (6) | (9) | (15) | (26) | (24) | – | – | – | – | – |
| Income tax expense | – | – | – | – | (24) | (13) | 0 | – | – | – |
| Net income from continuing operations | (6) | – | – | – | 0 | – | – | – | – | – |
| Net income | (6) | (9) | (15) | (26) | (24) | (13) | (26) | (17) | (25) | (34) |